GHSI vs. CMMB, ATHE, AEZS, ADXN, MTEM, GRTX, ERNA, ABVC, MIRA, and MBRX
Should you be buying Guardion Health Sciences stock or one of its competitors? The main competitors of Guardion Health Sciences include Chemomab Therapeutics (CMMB), Alterity Therapeutics (ATHE), Aeterna Zentaris (AEZS), Addex Therapeutics (ADXN), Molecular Templates (MTEM), Galera Therapeutics (GRTX), Eterna Therapeutics (ERNA), ABVC BioPharma (ABVC), MIRA Pharmaceuticals (MIRA), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical preparations" industry.
Guardion Health Sciences (NASDAQ:GHSI) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability.
In the previous week, Chemomab Therapeutics had 2 more articles in the media than Guardion Health Sciences. MarketBeat recorded 5 mentions for Chemomab Therapeutics and 3 mentions for Guardion Health Sciences. Guardion Health Sciences' average media sentiment score of 0.34 beat Chemomab Therapeutics' score of 0.29 indicating that Guardion Health Sciences is being referred to more favorably in the media.
20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Guardion Health Sciences has higher revenue and earnings than Chemomab Therapeutics. Guardion Health Sciences is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.
Chemomab Therapeutics has a net margin of 0.00% compared to Guardion Health Sciences' net margin of -16.69%. Guardion Health Sciences' return on equity of -77.29% beat Chemomab Therapeutics' return on equity.
Guardion Health Sciences has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Chemomab Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Chemomab Therapeutics has a consensus target price of $5.67, suggesting a potential upside of 573.80%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Guardion Health Sciences.
Guardion Health Sciences received 46 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.39% of users gave Guardion Health Sciences an outperform vote while only 61.54% of users gave Chemomab Therapeutics an outperform vote.
Summary
Chemomab Therapeutics beats Guardion Health Sciences on 9 of the 17 factors compared between the two stocks.
Get Guardion Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardion Health Sciences Competitors List
Related Companies and Tools
